DDInter1878 DDInter1747
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Tripelennamine {u} (Compound) resembles {v} (Compound) Dimetacrine
Tripelennamine {u} (Compound) resembles {v} (Compound) Chloropyramine
Tripelennamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brompheniramine
Tripelennamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Tripelennamine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Tripelennamine {u} (Compound) binds {v} (Gene) HRH1
Tripelennamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Tripelennamine {u} may lead to a major life threatening interaction when taken with {v} Zonisamide
Tripelennamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Disopyramide
Tripelennamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orphenadrine
Tripelennamine (Compound) resembles Dimetacrine (Compound)
Tripelennamine (Compound) resembles Chloropyramine (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Tripelennamine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Tripelennamine (Compound) binds HRH1 (Gene)
Tripelennamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Tripelennamine may lead to a major life threatening interaction when taken with Zonisamide
Tripelennamine (Compound) resembles Disopyramide (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide
Tripelennamine (Compound) resembles Orphenadrine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine